ACE-083Check methods and identity
What newer muscle imaging adds to the ACE-083 story
2 numbered sourcesSource years 2022, 2026
Peptides are short chains of amino acids held together by peptide bonds. Some bind larger molecules and change how cells receive signals. ACE-083 is a larger engineered fusion protein made from modified follistatin and the Fc region of a human antibody. It was designed to capture signals that restrict muscle growth near the muscle under study. A 2026 imaging study in facioscapulohumeral muscular dystrophy, or FSHD, helps explain how researchers can detect tissue changes even when tests of movement change very little. The imaging study did not administer ACE-083. [1] [2]
Researchers scanned the lower legs of 31 people with FSHD and 30 matched controls. Twenty-seven patients returned for a scan about a year later. The fraction of tissue identified as fat increased on quantitative MRI, and muscles with intermediate levels of fat at the start tended to progress more. Clinical strength and mobility measures changed only modestly during the same period. In this context the scans picked up structural changes over a relatively short interval. [1]
The earlier ACE-083 trial used MRI for a different purpose. It compared a treated group with a placebo group and measured total muscle volume, along with estimated contractile volume and fat fraction. The trial found a volume increase in targeted muscles and inconsistent changes in tests of movement and in outcomes reported by participants. Fat fraction and volume are separate measurements. A muscle can become larger even if the proportion made up by fat stays similar. [2]
The 2026 study followed disease progression, while the 2022 trial measured response to an experimental intervention. Read together, they illustrate why a trial might include a sensitive measure of tissue change and a separate measure of what people can do. [1] [2]
Sources
Original works cited in this article. Links open the external record in a new tab.
